Brief: Enlivex Announces Topline Results Of Phase II Trial Evaluating Allocetra In Patients With Sepsis
11/04/2024 15:20
April 11 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES TOPLINE RESULTS OF ITS PHASE II TRIAL
EVALUATING ALLOCETRA™ IN PATIENTS WITH SEPSIS
* ENLIVEX THERAPEUTICS LTD - POSITIVE INDICATION OF EFFECT
AND
SAFETY RESULTS FROM ITS PHASE II STUDY OF ALLOCETRA IN PATIENTS
WITH SEPSIS
* ENLIVEX THERAPEUTICS: STUDY SHOWED SUBSTANTIAL SOFA SCORE
REDUCTIONS, LOW MORTALITY RATE OF ALLOCETRA TREATED PATIENTS
ACROSS ALL ORIGINS OF SEPSIS
Source text for Eikon: ID:nGNX4CJpj4
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment